Trial Profile
Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Sep 2009 Actual patient number (522) added as reported by ClinicalTrials.gov.
- 10 Jun 2009 Planned end date changed from 1 Jul 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.